The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Open accessAbstract
BACKGROUND: Peginterferon-ribavirin therapy is the current standard of care for chronic infection with hepatitis C virus (HCV). The rate of sustained virologic response has been below 50% in cases of HCV genotype 1 infection. Boceprevir, a potent oral HCV-protease inhibitor, has been evaluated as an additional treatment in phase 1 and phase 2 studies. METHODS: We conducted a double-blind study in which previously untreated adults with HCV genotype 1 infection were randomly assigned to one of three groups. In all three groups, peginterferon alfa-2b and ribavirin were administered for 4 weeks (the lead-in period). Subsequently, group 1 (the control group) received placebo plus peginterferon-ribavirin for 44 weeks; group 2 received boceprevir plus peginterferon-ribavirin for 24 weeks, and those with a detectable HCV RNA level between weeks 8 and 24 received placebo plus peginterferon-ribavirin for an additional 20 weeks; and group 3 received boceprevir plus peginterferon-ribavirin for 44 weeks. Nonblack patients and black patients were enrolled and analyzed separately. RESULTS: A total of 938 nonblack and 159 black patients were treated. In the nonblack cohort, a sustained virologic response was achieved in 125 of the 311 patients (40%) in group 1, in 211 of the 316 patients (67%) in group 2 (P<0.001), and in 213 of the 311 patients (68%) in group 3 (P<0.001). In the black cohort, a sustained virologic response was achieved in 12 of the 52 patients (23%) in group 1, in 22 of the 52 patients (42%) in group 2 (P=0.04), and in 29 of the 55 patients (53%) in group 3 (P=0.004). In group 2, a total of 44% of patients received peginterferon-ribavirin for 28 weeks. Anemia led to dose reductions in 13% of controls and 21% of boceprevir recipients, with discontinuations in 1% and 2%, respectively. CONCLUSIONS: The addition of boceprevir to standard therapy with peginterferon-ribavirin, as compared with standard therapy alone, significantly increased the rates of sustained virologic response in previously untreated adults with chronic HCV genotype 1 infection. The rates were similar with 24 weeks and 44 weeks of boceprevir. (Funded by Schering-Plough [now Merck]; SPRINT-2 ClinicalTrials.gov number, NCT00705432.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Self-citationManns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
Self-citationTorriani, F. J., Rodriguez-Torres, M., Rockstroh, J. K., Lissen, E., Gonzalez-García, J., Lazzarin, A., Carosi, G., Sasadeusz, J., Katlama, C., Montaner, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040842 · Cited by 1,233
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
McHutchison, J. G., Lawitz, E. J., Shiffman, M. L., Muir, A. J., Galler, G. W., McCone, J., Nyberg, L. M., Lee, W. M., Ghalib, R. H., Schiff, E. R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808010 · Cited by 1,190
Self-citationTelaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
McHutchison, J. G., Everson, G. T., Gordon, S. C., Jacobson, I. M., Sulkowski, M., Kauffman, R., McNair, L., Alam, J., & Muir, A. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806104 · Cited by 1,089
Self-citationTelaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
Hézode, C., Forestier, N., Dusheiko, G., Ferenci, P., Pol, S., Goeser, T., Bronowicki, J.-P., Bourlière, M., Gharakhanian, S., Bengtsson, L., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807650 · Cited by 1,025
Self-citationEpidemiology of Hepatitis C: Geographic Differences and Temporal Trends
Wasley, A., & Alter, M. J. (2000) · Seminars in Liver Disease · doi:10.1055/s-2000-9506 · Cited by 979
Global surveillance and control of hepatitis C
(1999) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.1999.6120139.x · Cited by 904
Chung, R. T., Andersen, J., Volberding, P., Robbins, G. K., Liu, T., Sherman, K. E., Peters, M. G., Koziel, M. J., Bhan, A. K., Alston, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032653 · Cited by 875
Thompson, A. J., Muir, A. J., Sulkowski, M. S., Ge, D., Fellay, J., Shianna, K. V., Urban, T., Afdhal, N. H., Jacobson, I. M., Esteban, R., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.013 · Cited by 723
Self-citation
Cited by
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
EASL Recommendations on Treatment of Hepatitis C 2018
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.026 · Cited by 2,827
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,204
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S. C., Schultz, M., Davis, M. N., Kayali, Z., Reddy, K. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214853 · Cited by 1,788
Self-citationChalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.001 · Cited by 1,775
Tsochatzis, E. A., Bosch, J., & Burroughs, A. K. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60121-5 · Cited by 1,740
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Afdhal, N., Zeuzem, S., Kwo, P., Chojkier, M., Gitlin, N., Puoti, M., Romero-Gomez, M., Zarski, J.-P., Agarwal, K., Buggisch, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402454 · Cited by 1,705
Self-citationBoceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Bacon, B. R., Gordon, S. C., Lawitz, E., Marcellin, P., Vierling, J. M., Zeuzem, S., Poordad, F., Goodman, Z. D., Sings, H. L., Boparai, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009482 · Cited by 1,626
Self-citationGlobal distribution and prevalence of hepatitis C virus genotypes
Messina, J. P., Humphreys, I., Flaxman, A., Brown, A., Cooke, G. S., Pybus, O. G., & Barnes, E. (2015) · Hepatology · doi:10.1002/hep.27259 · Cited by 1,589
van der Meer, A. J., Veldt, B. J., Feld, J. J., Wedemeyer, H., Dufour, J.-F., Lammert, F., Duarte-Rojo, A., Heathcote, E. J., Manns, M. P., Kuske, L., et al. (2012) · JAMA · doi:10.1001/jama.2012.144878 · Cited by 1,510
Self-citationDaclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Sulkowski, M. S., Gardiner, D. F., Rodriguez-Torres, M., Reddy, K. R., Hassanein, T., Jacobson, I., Lawitz, E., Lok, A. S., Hinestrosa, F., Thuluvath, P. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306218 · Cited by 1,190
Self-citationEASL Recommendations on Treatment of Hepatitis C 2015
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.03.025 · Cited by 1,156
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Kowdley, K. V., Gordon, S. C., Reddy, K. R., Rossaro, L., Bernstein, D. E., Lawitz, E., Shiffman, M. L., Schiff, E., Ghalib, R., Ryan, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402355 · Cited by 1,130
Self-citationGhany, M. G., Nelson, D. R., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2011) · Hepatology · doi:10.1002/hep.24641 · Cited by 1,076
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
Feld, J. J., Kowdley, K. V., Coakley, E., Sigal, S., Nelson, D. R., Crawford, D., Weiland, O., Aguilar, H., Xiong, J., Pilot-Matias, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315722 · Cited by 903
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
Poordad, F., Hezode, C., Trinh, R., Kowdley, K. V., Zeuzem, S., Agarwal, K., Shiffman, M. L., Wedemeyer, H., Berg, T., Yoshida, E. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402869 · Cited by 874
Self-citationEASL Clinical Practice Guidelines: Management of hepatitis C virus infection
(2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.003 · Cited by 855
Morgan, R. L., Baack, B., Smith, B. D., Yartel, A., Pitasi, M., & Falck-Ytter, Y. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-5-201303050-00005 · Cited by 829
Lawitz, E., Sulkowski, M. S., Ghalib, R., Rodriguez-Torres, M., Younossi, Z. M., Corregidor, A., DeJesus, E., Pearlman, B., Rabinovitz, M., Gitlin, N., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61036-9 · Cited by 818
Self-citationABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Ferenci, P., Bernstein, D., Lalezari, J., Cohen, D., Luo, Y., Cooper, C., Tam, E., Marinho, R. T., Tsai, N., Nyberg, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402338 · Cited by 693
Self-citationUnderstanding the hepatitis C virus life cycle paves the way for highly effective therapies
Scheel, T. K. H., & Rice, C. M. (2013) · Nature Medicine · doi:10.1038/nm.3248 · Cited by 554
Lawitz, E., Poordad, F. F., Pang, P. S., Hyland, R. H., Ding, X., Mo, H., Symonds, W. T., McHutchison, J. G., & Membreno, F. E. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62121-2 · Cited by 547
Self-citationNew Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
Pawlotsky, J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.003 · Cited by 518
Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
Zeuzem, S., Jacobson, I. M., Baykal, T., Marinho, R. T., Poordad, F., Bourlière, M., Sulkowski, M. S., Wedemeyer, H., Tam, E., Desmond, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401561 · Cited by 517
Self-citationCurrent and Future Therapies for Hepatitis C Virus Infection
Liang, T. J., & Ghany, M. G. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1213651 · Cited by 490
Martin, N. K., Vickerman, P., Grebely, J., Hellard, M., Hutchinson, S. J., Lima, V. D., Foster, G. R., Dillon, J. F., Goldberg, D. J., Dore, G. J., et al. (2013) · Hepatology · doi:10.1002/hep.26431 · Cited by 488
Rosen, H. R. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1006613 · Cited by 487
Webster, D. P., Klenerman, P., & Dusheiko, G. M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62401-6 · Cited by 439
Jacobson, I. M., Dore, G. J., Foster, G. R., Fried, M. W., Radu, M., Rafalsky, V. V., Moroz, L., Craxi, A., Peeters, M., Lenz, O., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60494-3 · Cited by 437
Self-citationTreatment of Hepatitis C: A Systematic Review
Kohli, A., Shaffer, A., Sherman, A., & Kottilil, S. (2014) · JAMA · doi:10.1001/jama.2014.7085 · Cited by 426
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
Sarrazin, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.09.011 · Cited by 423
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
Bartenschlager, R., Lohmann, V., & Penin, F. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3046 · Cited by 402
Manns, M., Marcellin, P., Poordad, F., de Araujo, E. S. A., Buti, M., Horsmans, Y., Janczewska, E., Villamil, F., Scott, J., Peeters, M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60538-9 · Cited by 376
Self-citationAndreone, P., Colombo, M. G., Enejosa, J. V., Koksal, I., Ferenci, P., Maieron, A., Müllhaupt, B., Horsmans, Y., Weiland, O., Reesink, H. W., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.04.045 · Cited by 365
Chhatwal, J., Kanwal, F., Roberts, M. S., & Dunn, M. A. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1336 · Cited by 338
From non-A, non-B hepatitis to hepatitis C virus cure
Pawlotsky, J.-M., Feld, J. J., Zeuzem, S., & Hoofnagle, J. H. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.006 · Cited by 328
Koh, C., Li, Q., & Liang, J. (2016) · Clinical Virology · doi:10.1128/9781555819439.ch54 · Cited by 321
Cell and tissue engineering for liver disease
Bhatia, S. N., Underhill, G. H., Zaret, K. S., & Fox, I. J. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3005975 · Cited by 309
Hepatocellular carcinoma: old friends and new tricks
Kim, E., & Viatour, P. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00527-1 · Cited by 307
Smith, B. D., Morgan, R. L., Beckett, G. A., Falck-Ytter, Y., Holtzman, D., & Ward, J. W. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-9-201211060-00529 · Cited by 302
Hepatitis C Virus Proteins: From Structure to Function
Moradpour, D., & Penin, F. (2013) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-27340-7_5 · Cited by 301
Osinusi, A., Meissner, E. G., Lee, Y.-J., Bon, D., Heytens, L., Nelson, A., Sneller, M., Kohli, A., Barrett, L., Proschan, M., et al. (2013) · JAMA · doi:10.1001/jama.2013.109309 · Cited by 291
Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
Poordad, F., Lawitz, E., Kowdley, K. V., Cohen, D. E., Podsadecki, T., Siggelkow, S., Heckaman, M., Larsen, L., Menon, R., Koev, G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208809 · Cited by 285
Self-citationAntiviral strategies in hepatitis C virus infection
Sarrazin, C., Hézode, C., Zeuzem, S., & Pawlotsky, J.-M. (2012) · Journal of Hepatology · doi:10.1016/s0168-8278(12)60010-5 · Cited by 283
Global control of hepatitis C: where challenge meets opportunity
Thomas, D. L. (2013) · Nature Medicine · doi:10.1038/nm.3184 · Cited by 280
Fried, M. W., Buti, M., Dore, G. J., Flisiak, R., Ferenci, P., Jacobson, I., Marcellin, P., Manns, M., Nikitin, I., Poordad, F., et al. (2013) · Hepatology · doi:10.1002/hep.26641 · Cited by 272
Self-citationPhase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1
Kowdley, K. V., Lawitz, E., Poordad, F., Cohen, D. E., Nelson, D. R., Zeuzem, S., Everson, G. T., Kwo, P., Foster, G. R., Sulkowski, M. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306227 · Cited by 255
Self-citationHepatitis C infection, antiviral treatment and mental health: A European expert consensus statement
Schaefer, M., Capuron, L., Friebe, A., Diez-Quevedo, C., Robaeys, G., Neri, S., Foster, G. R., Kautz, A., Forton, D., & Pariante, C. M. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.037 · Cited by 225
Shen, F., Sun, B., Kreutz, J. E., Davydova, E. K., Du, W., Reddy, P. L., Joseph, L. J., & Ismagilov, R. F. (2011) · Journal of the American Chemical Society · doi:10.1021/ja2060116 · Cited by 231
Advances in hepatitis C therapy: what is the current state - what come's next?
Zopf, S. (2016) · World Journal of Hepatology · doi:10.4254/wjh.v8.i3.139 · Cited by 91
Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C
Younossi, Z. M., Stepanova, M., Afendy, M., Lam, B. P., & Mishra, A. (2013) · Journal of Viral Hepatitis · doi:10.1111/jvh.12080 · Cited by 42
Bonner, J. E., Barritt, A. S., Fried, M. W., & Evon, D. M. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2141-4 · Cited by 32
Chronic hepatitis C and antiviral treatment regimens: Where can psychology contribute?
Evon, D. M., Golin, C. E., Fried, M. W., & Keefe, F. J. (2013) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0029030 · Cited by 32
Arora, S. S., Axley, P., Ahmed, Z., Satapathy, S. K., Wong, R., Kuo, Y., & Singal, A. K. (2019) · Transplant International · doi:10.1111/tri.13424 · Cited by 24
Clinical Aspects of Liver Transplantation
Mangus, R. S., & Tector, A. J. (2011) · Practical Hepatic Pathology: A Diagnostic Approach · doi:10.1016/b978-0-443-06803-4.00041-1 · Cited by 1
Metadata
- Authors
- Poordad, F., McCone, J., Bacon, B. R., Bruno, S., Manns, M. P., Sulkowski, M. S., Jacobson, I. M., Reddy, K. R., Goodman, Z. D., Boparai, N., DiNubile, M. J., Sniukiene, V., Brass, C. A., Albrecht, J. K., & Bronowicki, J.-P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-03-31
- Volume
- 364
- Issue
- 13
- Pages
- 1195-1206
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2143559032
- Cited by
- 2,520
- References
- 16
- FWCI
- 289.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.